				ATTORNEY'S DKT NO.		APPLICATION NO.		
INFORMATION DISCLOSURE			O12712-919 APPLICANT	Unassigned				
CITATION			Paul CHINN	04	1628,181	98. °		
PTO-1449			FILING DATE July 28, 2000		GROUP /64 Unassigned	و28. ۲		
<u></u>	U.S. PATENT DO			OCUMENTS			693	
EXAMINER'S INITIALS	PATENT NO.	DATE		NAME	CLASS	SUBCLASS	FILING DAT	
Des	4,361,544	11/30/82	Goldenberg		-	UUDULASS	<del> </del>	
Das	4,460,559	7/17/84	Goldenberg		_			
Day	4,460,561	7/17/84	Goldenberg				<del> </del>	
Leus	4,348,376	9/7/82	Goldenberg					
Des	4,331,647	5/25/82	Goldenberg				†	
Lu	5,376,356	12/27/94	Morgan, Jr.					
well	5,363,846	11/15/94	Rubin et al	<del> </del>		-		
Sud	5,130,118	7/14/92	Johnson et al	· · · · · · · · · · · · · · · · · · ·				
Loel	5,162,115	11/10/92	Pietronigro					
Sul	5,208,008	5/4/93	Ranadive et al					
way	4,767,609	8/30/88	Stavrianpoulos	3				
Dut	4,855,353	8/8/89	Kurami et al				,	
Das	4,315,851	2/16/82	Yoshikumi et a	al				
		FORE	IGN PATENT D	OCUMENTS		100	11 11 1	
EXAMINER'S INITIALS	PATENT NO.	DATE	cou	NTRY	CLASS	SUBCLASS	Translation Yes No	
						GODGEAGG	Tes No	
	OTHER DOCU	MENTS (Inc	luding Author,	Title, Date, Perti	nent Page	s, Etc.)		
Dus	Kukis et al, "Opt Nucl. Med. 1998	imized Cond	itions for Chela	tion of Yttrium-9	0-DOTA	lmmunoconji	ugates", J.	
Lion	Griffiths et al, "Rapid, facile and quantitative radiolabeling of DOTA-hMAb conjugates with Y-90 cancer radioimmunotherapy", Abstract from AACR Meeting, No. 4242							
all	Pai-Scherf et al, "Imaging and phase I study of 111 In- and 90Y-labeled anti-Lewis" monoclonal antibody", Abstract from AACR Meeting No. 4240							
skil I	Kobayashi et al, "Pharmacokinetics of In-111 and I-125 labeled anti-Tac single-chain Fv recombinant immunotoxin (LMB2), Abstract from AACR Meeting No. 4239							
EXAMINER DATE CONSIDERED 4/2/02								

SHEET 2 OF 3

INFORMATION DISCLOSURE			012712-919		APPLICATION No. Unassigned		
	CITA		/001.2	APPLICANT Paul CHINN			
				FILING DATE		GROUP	
	PTO-1		Ů.S. PATENT DO	July 28, 2000	**************************************	Unassigned	
EXAMINER'S					The B		FILING DAT
INITIALS	PATENT NO. 4,401,592	DATE 8/30/83	Yoshikumi et	NAME al	CLASS	SUBCLASS	112
Dal	5,219,556	6/15/93	Wolfangel	aı		+	<b></b>
on	4,707,352	11/17/87	Stavrianpoulos	ne	+		
Jan J	5,403,573	4/4/95	Day et al				<del></del>
Lond	5,059,518	10/22/91	Kortright et al				
194	5,641,637	6/24/97	Hudak et al		+=		
seil	3,994,966	11/30/76	Sundberg et al	ıl			
Jour	4,043,998	8/23/77	Meares et al		<del></del>		
Lows	4,622,420	11/11/86	Meares et al				
Dus	4,722,892	2/2/88	Meares et al				
Dul	5,286,850	2/15/94	Gansoh et al				
Dus	4,923,985	5/8/90	Gansow et al				
soul!	5,124,471	6/23/92	Gansow et al				
Dus	5,428,154	6/27/95	Gansow et al				
Dus	5,434,287	7/18/95	Gansow et al				
Duj	5,500,362	3/19/96	Robinson et al				
Lley	4,831,175	5/16/89	Gansow et al			_	
Sucs	5,009,069	4/23/91	Molini				
Day	5,545,403	8/13/96	Page				-
		FORF	EIGN PATENT D	OCUMENTS			
EXAMINER'S INITIALS	PATENT NO.	DATE	COU	INTRY	CLASS	SUBCLASS	Translation Yes No
			market seek at 3 control of the 3 control of the seek at 3 control of the seek at 3 control of t			The way was the control of the contr	
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		F 3 24 1		1	jud.	
EXAMINER	David a	Stern	sus DA-	TE CONSIDERED	9/2	2/02	
				_	•	,	,

SHEET <u>3</u> OF <u>3</u>

INFORMATION DISCLOSURE CITATION				ATTORNEY'S DKT NO. 012712-919		APPLICATION NO. Unassigned		
				APPLICANT Paul CHINN		<del></del>		
				FILING DATE		GROUP		
	PTO-	entition of the state of the st		July 28, 2000		Unassigned		
EXAMINER'S		T T	I.S. PATENT DO	CUMENTS				
INITIALS	PATENT NO.	DATE	N	IAME	CLASS	SUBCLASS	FILING DAT	
sous	5,246,692	9/21/93	Gansow et al					
Dela	4,454,106	6/12/84	Gansow et al					
sou!	4,824,986	4/25/89	Gansow et al			1		
Low	4,472,509	9/18/84	Gansow et al			1		
Dus	4,861,579	8/29/89	Meyer, Jr. et	al				
sul	5,101,827	4/7/92	Goldenberg	<u> </u>	-			
Low	4,444,744	4/24/84	Goldenberg					
soul	4,735,210	4/5/88	Goldenberg					
Low	4,634,586	1/6/87	Goodwin et al					
Duy	5,034,223	7/23/91	Abrams et al					
Dus	4,921,690	5/1/90	Beatty et al					
Local	5,595,721	1/21/97	Kaminski et al		_			
Das	5,545,405	8/13/96	Page		_			
1.00	The state of the s	FORE	IGN PATENT D	OCUMENTS				
EXAMINER'S INITIALS	PATENT NO.	DATE	cour	NTRY	CLASS	SUBCLASS	Translation	
						COBOLAGO	Yes No	
							700	
EXAMINER 5	Facial a.	Laure	leer DAT	E CONSIDERED		1, 5/2		
		====			4/	1-810		

ATTORNEY'S DKT NO. APPLICATION NO. INFORMATION DISCLOSURE 012712-919 Unassigned 6 APPLICANT CITATION Paul CHINN FILING DATE GROUP PTO-1449 Unassigned 6 July 28, 2000 U.S. PATENT DOCUMENTS **EXAMINER'S** INITIALS **FILING DATE** PATENT NO. DATE NAME CLASS SUBCLASS 6,010,680 1/4/00 Govindan et al 5,976,492 11/2/99 Griffiths et al FOREIGN PATENT DOCUMENTS **EXAMINER'S** Translation INITIALS PATENT NO. DATE COUNTRY CLASS **SUBCLASS** Yes OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Grossbard et al, "Monoclonal Antibody-Based Therapies of Leukemia and Lymphoma", Blood 80(4):863-876 (1992) Applebaum, "Radiolabeled Monoclonal Antibodies in Treatment of NHL", Hematology/ Oncology Clinics of North America 5(5):1013-1025 (1991) Larson et al, "Comparison of Bone Marrow Dosimetry and Toxic Effect of High Dose...to Man", Nucl. Med. Biol. 16(2):153-158 (1989) Reilly, "Radioimmunotherapy of Malignancies", Clin. Pharm. 10(5):359-375 (1991) Stewart et al, "Intraperitoneal 131 l- and 90Y-labeled Monoclonal Antibodies for Ovarian Cancer: Pharmocokinetics and ... Dosimetry", Int. J. Cancer Suppl. 3:71-76 (1988) Kaminski et al, "131 Anti-B1: Initial Clinical Evaluation in B Cell Lymphoma", Third Conference on Radioimmunodetection and ... Cancer", Abstract No. 144, (1990) Kaminski et al, "Initial Clinical Radioimmunotherapy Results with 131 (Anti-CD20) in Refractory B Cell Lymphoma", Fourth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer Antibody..., 5(3) Abstract No. 57

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

**EXAMINER** 

Catherine G

SHEET 1 OF 2

INFORMATION DISCLOSURE				ATTORNEY'S DKT NO. 012712-645		APPLICATION No. Unassigned o			
				APPLICANT Unassigned			200		
CITATION			Paul CHINN	<del></del>	- Kin				
	PTO-1449			FILING DATE March 1, 1999		GROUP/897 Unassigned	0.5 62.5		
			.S. PATENT DO	DCUMENTS			893		
EXAMINER'S INITIALS	PATENT NO.	DATE	1	NAME	CLASS	SUBCLASS	FIEING	DATE	
Dus	5,830,431	11/3/98	Srinivasan et	al	424	1.69			
Jul	5,820,845	10/13/98	Dean et al		424	1.41			
WAS.	5,766,571	6/16/98	Ceriani et al		424	1.49			
Das	5,698,178	12/16/99	Goldenberg		424	1.49			
Dus	5,620,675	4/15/97	McBride et al		424	1,69			
DUS	5,217,704	6/8/93	Johnson et al	٠.	424	1, 1			
Das	5,130,118	7/14/92	Johnson et al		424	1.1			
		FOR	EIGN PATENT	DOCUMENTS					
EXAMINER'S INITIALS	PATENT NO.	DATE	СО	UNTRY	CLASS	SUBCLASS	Transl	lation No	
Dal	O 315188 A2	5/10/89	Europe				155	1	
Dus	0 315188 B1	5/10/89	Europe	·					
Dal	W096/14879	5/23/96	PCT						
4									
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
Dus	Nicholson et al, "Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advancedanalysis", Oncology Reports, 5:223-226, 1998								
Sul	Hird et al, "Adju	vant therapy	y of ovarian ca	ncer with radioac			ody", E	3r. J.	
Luc	Richardson et al, "Optimization and batch production of DTPA-labelled antibody kits for routine use in <sup>111</sup> In immunoscintigrapy", Nucl. Med. Communications, 8:347-356, 1987								
sul				90 for Radioimmu					
23	1987								
Say	Fluid", Nucl. Me	d. Biol., 15(	3):285-292, 19	· <del></del>					
Lucy	Washburn et al, Potential Agent.	"Preclinical Carcinoma	Assessment of , Nucl. Med. B	f <sup>90</sup> Y-Labeled Mor liol., 15(6):707-7	noclonal A 11, 1988	intibody CO1	17-1A,	а	
Du		et al, "Labe		lonal Antibody Co			ppl. Ra	diat.	
Loves		"The Chemic		-DOTA Forbed by	/ β— Deca	y of <sup>212</sup> Pb(D	OTA) <sup>2</sup> "	,	
	114410011111104	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	10, 1000	<del></del>					
EXAMINER	David	aSa	under DA	ATE CONSIDERED	9/2	7/02			

						SHE	ET _2_	OF _
INFORMATION DISCLOSURE				ATTORNEY'S DKT NO. 012712-645		APPLICATION NO.		
INFORMATION DISCLOSURE			012712-645 Unassigned					
CITATION				Paul CHINN				
				FILING DATE		Chave		
	PTO-1	449		March 1, 1999		GROUP Unassigned		
		11	.S. PATENT DO	CURSENIES		Gridsbigried		
EXAMINER'S			S. FATENT DO	COIVIENTS				
INITIALS	PATENT NO.	DATE	1	IAME	CLASS	SUBCLASS	FILING DAT	
		,		7 (171)	CLASS		-	
				·			-	
		·						
								33333333333333
EVANINEDIO	<u> </u>	FOR	EIGN PATENT	DOCUMENTS				
EXAMINER'S INITIALS	PATENT NO.	DATE C		INTEN			Trans	lation
	TATENTINO. DATE CO		JNTRY	CLASS	SUBCLASS	Yes	No	
					1			İ
4_4	·							
	OTHER DOCUMENTS II. I.							
- 0	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
des	Brechbiel et al, "Synthesis of C-Functionalized trans-Cyclohexyldiethylenetriaminepenta- acetic Acids for LabellingEmitter", J. Chem. Soc. Perkin Trans., 1173-1178, 1992							
Jul	Izard et al, "An Improved Method for Labelling Monoclonal Antibodies with Semarium 152.							
00	Use of the Bifunctional ChelateAcid", Bioconjugate Chem, 3(4), 346-350, 1992							
Sul	Huneke et al, "Effective α-Particle-mediated Radioimmunotherapy of Murine Leukimia", Cancer Research, 52:5818-5820, 1992							
00				Liganda? Salar	ntion of FC	in anti		
$\sim D^{\omega}$ ,	Gansow et al, "Macrocyclic or Conventional Ligands? Selection of Effective ChelatorsRadioimmunotherapy", Chem. Sect., Radiation Oncol. Branch, Natl. Canc. Inst.							
Day.	Antisoma, Inter	net reference	. 16 pp		bia	non, Ivali. Ca	anc. III	<u> </u>
Dul	Antisoma, Internet reference, 16 pp.  Cytogen, Internet reference, 15 pp							
	- / togott	ot reference,	10 рр			·		
<del></del>								
		·						
EXAMINER (	Dand	U Sa	uncepa	TE CONSIDEREI	9/2	7/02		